CYP2C19 gene polymorphism combination with inflammatory cell ratios was significant in the prognosis of coronary heart disease. A cross-sectional analysis study, with 6 months follow-up on 142 patients with acute coronary syndrome. Patients were analyzed for CYP2C19 gene polymorphisms by real-time polymerase chain reaction (PCR) and complete blood count to determine inflammatory cell ratios and recorded cardiovascular events (CEs) after following up to 6 months. For 90-day CEs, CYP2C19 gene polymorphism (Hazard Ratio (HR): 1.965, 95 % Confidence Interval (CI): 1.012–3.814), the combination of a neutrophil and lymphocyte ratio (NLR) ≥ 2.982 (HR: 13.001, 95 % CI: 1.37–97.304) or a platelet to lymphocyte ratio (PLR) ≥ 162.42 (HR: 2.878, 95 % CI: 1.212–6.835) was independent predictors of CEs. For 180-day CEs, CYP2C19 gene polymorphism combination with NLR ≥3.02 (HR: 13.946, 95 % CI: 1.833–106.121) or PLR ≥160.38 (HR: 5.349, 95 % CI: 1.379–20.745) or monocyte to lymphocyte ratio (MLR) ≥ 0.3 (HR: 4.699, 95 % CI: 1.032–31.393) were independent predictors of CEs. NLR, PLR or MLR combined with CYP2C19 gene polymorphism were stronger independent predictors of cardiovascular events in patients with acute coronary syndromes compared to CYP2C19 gene polymorphism and inflammatory cell ratios separately. CYP2C19 polymorphism and high NLR was the strongest predictor of both CEs at 90 days and 180 days.

Intravenous iron supplementation, particularly ferric carboxymaltose (FCM), has emerged as an effective therapeutic strategy for correcting iron deficiency (ID) in patients with heart failure with reduced ejection fraction (HFrEF). However, the enhancement related to the quality of life (QoL) and functional capacity remains unclear, specifically in the Vietnam population. This study assesses the enhancement of QoL and functional capacity in intravenous FCM therapy in heart failure patients with ID. We conducted a cross-sectional analysis study in patients with chronic HFrEF. Eligible patients diagnosed with ID were treated with FCM. Endpoint was the improvement in QoL, assessed by the European Quality of Life 5 Dimensions 5 Level Version questionnaire, and functional capacity, measured by the change in the 6-minute walk test and New York Heart Association Functional Classification. A total of 132 patients with chronic HFrEF, with 35.60% of patients with ID. The study population had a mean age of 65.7 ± 9.4 years, males accounted for 56.8%. Female, New York Heart Association ≥3 and poor QoL significantly associated with ID. Notably, 12 weeks after intervention, patients with poor QoL decreased from 48.9% to 34.0% (P < .001). Functional capacity, assessed by the 6-minute walk test, improved with the median distance increasing from 239.90 (198.80–291.70) m at baseline to 262.60 (219.50–309.70) m (P < .01). Nausea was reported by a small minority at 4.25%. Our study highlights the significant burden of ID in patients with HFrEF, emphasizing its strong association with symptom severity, functional impairment, and reduced QoL. Intravenous FCM therapy demonstrated significant improvements in iron parameters, functional capacity, and QoL, with a favorable safety profile.

Background: Resistant hypertension (RH) presents significant clinical challenges, often precipitating a spectrum of cardiovascular complications. Particular attention recently has focused on the role of matrix metalloproteinase-2 (MMP-2) gene polymorphisms, implicated in hypertensive target organ damage (TOD). Despite growing interest, the specific contribution of MMP-2 polymorphisms to such damage in RH remains inadequately defined. Objective: This study is the first to examine the rs243865 (−1306C>T) polymorphism in the MMP-2 gene in the Vietnamese population and patients with RH, underscoring its critical role as a genetic determinant of TOD. Methods: A cross-sectional study with both descriptive and analytical components was conducted with 78 patients with RH at the Can Tho Central General Hospital and Can Tho University of Medicine and Pharmacy Hospital from July 2023 to February 2024. Results: More than three-quarters of patients with RH had carotid-femoral pulse wave velocity (PWV) >10 m/s and microalbuminuria at a prevalence of 79% (62/78) and 76% (59/78), respectively, and more than half of patients with RH had left ventricular mass index, relative wall thickness, and carotid artery stenosis with a prevalence of 56% (45/78), 55% (43/78), and 53% (41/78), respectively. Of the 78 studied patients with RH, the presence of genotype CC was 77% (60/78), genotype CT accounted for 21% (16/78), and genotype TT for 3% (2/78). The presence of single nucleotide polymorphism rs243865 (−1306C>T) with allele T was 23% (18/78). The MMP-2 gene polymorphism 1306C/T (rs243865) was significantly associated with ejection fraction and carotid artery stenosis with odds ratios (ORs) 8.1 (95% CI 1.3‐51.4; P=.03) and 4.5 (95% CI 1.1‐20.1; P=.048), respectively. The allele T was found to be significantly associated with arterial stiffness including brachial-ankle PWV and carotid-femoral PWV with the correlation coefficient of OR 2.2 (95% CI 0.6‐3.8) and OR 1.8 (95% CI 0.5‐3.2), respectively. Conclusions: The MMP-2 gene polymorphism rs243865 (−1306C>T) may have an association with measurable TOD in RH.

Background: Mitral regurgitation (MR) is a common heart valve disease, causing many serious complications in several organ systems, especially the cardiovascular system. The 2D speckle tracking echocardiography (STE) is a new technique for detecting potential cardiac dysfunction when only tissue function abnormalities are present. The study aimed to assess left ventricular (LV) systolic function early by STE in patients with primary MR through global LV deformity along the global longitudinal strain (GLS). Methods: An analytical cross-sectional study was performed on 46 patients with moderate to severe primary MR as recommended by the American Society of Echocardiography (ASE) 2017. Results: The prevalence of patients with GLS reduction with ejection fraction (EF) >60%, New York Heart Association (NYHA) I, and left ventricular internal diameter systolic (LVIDs) <40mm was 38.1%, 35.7%, and 39.5%, respectively. 100% of patients with EF<60% and LVIDs40mm had reduced GLS (<16%). The GLS index strongly correlates with the NYHA classification, degree of MR, EF, and echocardiographic parameters. Conclusion: GLS index gives a significant sign in the early detection of cardiac function abnormalities before symptoms or other echocardiographic parameters in patients with MR.

Background: Apolipoprotein B (APOB) rs676210 polymorphism has been associated with altered lipid metabolism and cardiovascular risk in various populations; however, data from Vietnamese populations remain limited. Objective: This study aimed to investigate the association of the APOB rs676210 variant with lipid profiles among Vietnamese individuals newly diagnosed with elevated low-density lipoprotein cholesterol (LDL-C). Methods: A cross-sectional study was conducted among 69 Vietnamese adults newly diagnosed with elevated LDL-C (≥130 mg/dL) at a tertiary hospital in Southern Vietnam. Participants were genotyped for APOB rs676210 using real-time polymerase chain reaction (PCR) with allele-specific probes. Lipid profile components, including LDL-C, high-density lipoprotein cholesterol (HDL-C), non–HDL-C, and ApoB, were compared across genotype groups (AA vs GA/GG) and alleles (A vs G). Statistical analyses involved t tests, chi-square tests, and multivariable linear regression adjusted for age, sex, the BMI, and diabetes. P<.05 was considered statistically significant. Results: Of the 69 participants, 32 (46.4%) carried the AA genotype, while 37 (53.6%) carried the GA or the GG genotype. The AA genotype was associated with significantly higher LDL-C (mean 5.19, SD 0.95, vs mean 4.37, SD 0.97, mmol/L; P<.001), non–HDL-C (mean 5.94, SD 1.08, vs mean 5.31, SD 1.22 mmol/L; P=.03), and ApoB (mean 149.5, SD 26.3, vs mean 136.9, SD 15.2, mg/dL; P=.02) and lower HDL-C (mean 1.26, SD 0.31, vs mean 1.44, SD 0.39, mmol/L; P=.03) compared to the GA/GG genotype. Allele-based analysis showed that carriers of the A allele (98/138, 71%) also had higher LDL-C (mean 4.91, SD 1.02, vs mean 4.36, SD 0.97, mmol/L; P=.004) and ApoB (mean 145.6, SD 23.2, vs mean 135.9, SD 16.0, mg/dL; P=.02) than G allele carriers (40/138, 29%). These associations remained significant after multivariate adjustment. Conclusions: APOB rs676210 polymorphism is associated with significant differences in lipid profiles among Vietnamese adults with elevated LDL-C. Specifically, the A allele and the AA genotype confer a more atherogenic profile, suggesting potential utility as a genetic marker in lipid screening and personalized cardiovascular risk management in this population.